The Outlook For Precigen
Source: SeekingAlpha
2025-09-23 18:18:23 ET
Shares of gene and cell therapy concern Precigen, Inc. ( PGEN ) have rallied substantially since its recurrent respiratory papillomatosis therapy Papzimeos received full approval from the FDA on August 14th. The first-ever approval for the indication will provide the company with a nine-month plus first-mover advantage over a seemingly slightly inferior candidate from Inovio Pharmaceuticals’ ( INO ) . With pricing that would suggest a large total domestic market opportunity with a market cap of just over $1 billion, Precigen merited further investigation. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
The Outlook For Precigen
Precigen Inc.
NASDAQ: PGEN
PGEN Trading
4.34% G/L:
$3.475 Last:
1,226,008 Volume:
$3.32 Open:
PGEN Latest News
March 11, 2026 04:05:00 pm
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
January 20, 2026 08:05:00 am
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
January 12, 2026 08:00:00 am
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026 04:05:00 pm
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
PGEN Stock Data
$1,632,900,063
187,173,160
1.3%
60
N/A
Biotechnology & Life Sciences
Healthcare
US
Germantown
